乙型肝炎核心抗体：2020年在临床实践中的作用

StephenW

Hepatitis B Core Antibody: Role in Clinical Practice in 2020

    Robert G. Gish, Syed Abdul Basit, John Ryan, Altaf Dawood & Ulrike Protzer

Current Hepatology Reports volume 19, pages254–265(2020)Cite this article

    87 Accesses

    Metrics details

Abstract
Purpose of Review

It is crucial for clinicians to understand the need to screen for hepatitis B core antigen (anti-HBc status), proper interpretation of HBV biomarkers, and that “anti-HBc only” indicates HBV exposure, lifelong persistence of cccDNA with incomplete infection control, and potential risk for reactivation.
Findings

Many common misconceptions exist, including that tests for anti-HBc have high false-positive rates, that patients with anti-HBc alone or occult hepatitis B may profit from “vaccine boosting” to achieve immune control of HBV, and that anti-HBc(+)/anti-HBs(+) patients have cleared HBV when they have actually achieved immune control, while HBV persists in some hepatocytes and can reactivate.
Summary

This review breaks down several common misconceptions regarding anti-HBc with the most recent evidence. In addition, current best strategies for anti-HBc testing and interpretation are reviewed and summarized.

StephenW

乙型肝炎核心抗体：2020年在临床实践中的作用

    罗伯特·G·吉什（Robert G.

《当前肝病学报告》第19卷，第254–265页（2020年）

    87次访问

    指标详细信息

抽象
审查目的

对于临床医生来说，了解筛查乙型肝炎核心抗原（抗-HBc状况），正确解释HBV生物标志物的必要性以及“仅抗-HBc”指示HBV暴露，cccDNA的终生持续性以及不完全的感染控制是至关重要的，以及重新激活的潜在风险。
发现

存在许多常见的误解，包括抗HBc检测的假阳性率高，单独使用抗HBc或隐匿性乙型肝炎的患者可能会从“疫苗加强”中获益以实现对HBV的免疫控制，而抗HBc（ +）/抗-HBs（+）患者在实际达到免疫控制后便清除了HBV，而HBV仍存在于某些肝细胞中并可以重新激活。
摘要

这项审查以最新证据分解了关于抗-HBc的几种常见误解。此外，对当前抗HBc检测和解释的最佳策略进行了综述和总结。